Table 1.

Preclinical data with MEK inhibitors in non-small cell lung cancer.

Study	Type	Treatments used	Endpoints	Outcome
Chen et al. [2012]	Preclinical: xenograft model (KRAS-mutant lung cancer)	Selumitinib plus docetaxel	Assessment of the synergistic effect of both agents	The addition of selumetinib provided substantial benefit for mice with lung cancer caused by KRAS and KRAS and p53 mutations, but mice with KRAS and Lkb1 mutations had primary resistance to this combination therapy.
Mas et al. [2015]	Preclinical: 3D microenvironment tumor cells (OncCilAir).	Selumetinib	Assessment of the antitumor effects of selumetinib.	Tumors showed a reduced growth in response to the MEK inhibitors, but halting the selumetinib dosing resulted in tumor relapse.